Ono Pharmaceutical Co., Ltd. is a Japan-based biopharmaceutical company primarily engaged in the research, development and commercialization of therapeutic drugs. Headquartered in Osaka, the company concentrates on discovering novel treatments in oncology, immunology and other specialty areas. Ono leverages both small-molecule and biologic platforms to address unmet medical needs, with a focus on immune checkpoint inhibitors, targeted therapies and anti-inflammatory agents.
The company’s product portfolio is anchored by its oncology franchise, which includes collaborations on PD-1 inhibitor programs. Through strategic partnerships, Ono advances multiple clinical-stage candidates aimed at solid tumors and hematological malignancies. In addition to oncology, its pipeline spans autoimmune and inflammatory diseases, with proprietary compounds in various stages of preclinical and clinical development. The company also supplies active pharmaceutical ingredients (APIs) and finished dosage forms for domestic and international markets.
Ono Pharmaceutical maintains a global footprint, operating research centers and manufacturing facilities in Japan while collaborating with licensees and partners in North America, Europe and parts of Asia. Its international business development arm negotiates co-development and co-marketing agreements to expand patient access beyond its home market. Distribution networks and affiliate offices support commercial launches in key territories, reflecting Ono’s commitment to widening the reach of its innovations.
Tracing its roots to family-run apothecaries in the early 18th century, Ono Pharmaceutical has evolved into a publicly traded entity with a long history of innovation and collaboration. The company is governed by a board of directors and an executive leadership team based in Osaka, which oversees strategic planning, regulatory affairs and global operations. With a culture that emphasizes rigorous scientific inquiry and agile project management, Ono continues to invest in research capabilities and external alliances to drive the next generation of therapeutic breakthroughs.
AI Generated. May Contain Errors.
